1
|
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 2024:S0923-7534(24)00075-9. [PMID: 38490358 DOI: 10.1016/j.annonc.2024.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 02/29/2024] [Accepted: 03/01/2024] [Indexed: 03/17/2024] Open
Affiliation(s)
- T Powles
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK
| | - J Bellmunt
- Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Cancer Centre, Boston, USA
| | - E Comperat
- Department of Pathology, Medical University Vienna, Austria
| | - M De Santis
- Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - R Huddart
- Royal Marsden Hospital, Institute of Cancer Research, London, UK
| | - Y Loriot
- Department of Medical Oncology, Université Paris-Saclay and Gustave Roussy, Villejuif, France
| | - A Necchi
- Vita-Salute San Raffaele University, Milan; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy
| | - B P Valderrama
- Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain
| | - A Ravaud
- Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France
| | - S F Shariat
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York; Department of Urology, University of Texas Southwestern, Dallas, USA; Division of Urology, Department of Special Surgery, University of Jordan, Amman, Jordan
| | - B Szabados
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK
| | - M S van der Heijden
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S Gillessen
- Oncology Institute of Southern Switzerland (EOC-IOSI), Bellinzona; Università della Svizzera Italina (USI), Lugano, Switzerland
| |
Collapse
|
2
|
Heetman JG, van der Hoeven EJRJ, Rajwa P, Zattoni F, Kesch C, Shariat S, Dal Moro F, Novara G, La Bombara G, Sattin F, von Ostau N, Pötsch N, Baltzer PAT, Wever L, Van Basten JPA, Van Melick HHE, Van den Bergh RCN, Gandaglia G, Soeterik TFW. External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extension. Prostate Cancer Prostatic Dis 2023:10.1038/s41391-023-00738-3. [PMID: 37932522 DOI: 10.1038/s41391-023-00738-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 09/14/2023] [Accepted: 10/05/2023] [Indexed: 11/08/2023]
Abstract
BACKGROUND Prediction of side-specific extraprostatic extension (EPE) is crucial in selecting patients for nerve-sparing radical prostatectomy (RP). Multiple nomograms, which include magnetic resonance imaging (MRI) information, are available predict side-specific EPE. It is crucial that the accuracy of these nomograms is assessed with external validation to ensure they can be used in clinical practice to support medical decision-making. METHODS Data of prostate cancer (PCa) patients that underwent robot-assisted RP (RARP) from 2017 to 2021 at four European tertiary referral centers were collected retrospectively. Four previously developed nomograms for the prediction of side-specific EPE were identified and externally validated. Discrimination (area under the curve [AUC]), calibration and net benefit of four nomograms were assessed. To assess the strongest predictor among the MRI features included in all nomograms, we evaluated their association with side-specific EPE using multivariate regression analysis and Akaike Information Criterion (AIC). RESULTS This study involved 773 patients with a total of 1546 prostate lobes. EPE was found in 338 (22%) lobes. The AUCs of the models predicting EPE ranged from 72.2% (95% CI 69.1-72.3%) (Wibmer) to 75.5% (95% CI 72.5-78.5%) (Nyarangi-Dix). The nomogram with the highest AUC varied across the cohorts. The Soeterik, Nyarangi-Dix, and Martini nomograms demonstrated fair to good calibration for clinically most relevant thresholds between 5 and 30%. In contrast, the Wibmer nomogram showed substantial overestimation of EPE risk for thresholds above 25%. The Nyarangi-Dix nomogram demonstrated a higher net benefit for risk thresholds between 20 and 30% when compared to the other three nomograms. Of all MRI features, the European Society of Urogenital Radiology score and tumor capsule contact length showed the highest AUCs and lowest AIC. CONCLUSION The Nyarangi-Dix, Martini and Soeterik nomograms resulted in accurate EPE prediction and are therefore suitable to support medical decision-making.
Collapse
Affiliation(s)
- J G Heetman
- Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands
| | | | - P Rajwa
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - F Zattoni
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | - C Kesch
- Department of Urology, University Hospital Essen, Essen, Germany
| | - S Shariat
- Department of Urology, Medical University of Vienna, Vienna, Austria
- Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- Department of Special Surgery, The University of Jordan, Amman, Jordan
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia
- Department of Urology, Weill Cornell Medical College, New York, USA
| | - F Dal Moro
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | - G Novara
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | - G La Bombara
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | - F Sattin
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | - N von Ostau
- Department of Urology, University Hospital Essen, Essen, Germany
| | - N Pötsch
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - P A T Baltzer
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - L Wever
- Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands
| | - J P A Van Basten
- Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| | - H H E Van Melick
- Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands
| | | | - G Gandaglia
- Unit of Urology/Division of Oncology, San Raffaele Hospital, Milan, Italy
| | - T F W Soeterik
- Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
3
|
Mori K, Schuettfort V, Yanagisawa T, Katayama S, Laukhtina E, Pradere B, Rajwa P, Mostafaei H, Kimura T, Shariat S. Prognostic value of angiogenesis related marker vascular endothelial growth factor and vascular cell adhesion molecule-1 in bladder carcinoma treated with radical cystectomy. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01342-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
4
|
Barletta F, Gandaglia G, Robesti D, Bianchi L, Zattoni F, Dal Moro F, Reitano G, Rajwa P, Hübner N, Shariat S, Kesch C, Darr C, Fendler W, Gomez-Rivas J, Moreno-Sierra J, Ibañez L, Marra G, Guo H, Zhuang J, Amparore D, Checcucci E, Porpiglia F, Picchio M, Montorsi F, Briganti A. Identifying the optimal candidates for a super-extended staging pelvic lymph-node dissection in prostate cancer patients treated in the PET-PSMA era. Results from a multi-institutional series. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00700-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
5
|
Scuderi S, Gandaglia G, Barletta F, Bianchi L, Zattoni F, Dal Moro F, Reitano G, Rajwa P, Hübner N, Shariat S, Kesch C, Darr C, Fendler W, Gomez-Rivas J, Moreno-Sierra J, Marra G, Guo H, Zhuang J, Amparore D, Checcucci E, Porpiglia F, Schiavina R, Brunocilla E, Montorsi F, Briganti A. Improving prediction of local stage by PSMA-PET: Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01264-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
6
|
Piccinelli M, Panunzio A, Tappero S, Barletta F, Incesu RB, Luzzago S, Mistretta F, Nardini S, Tozzi M, Cozzi G, Bottero D, Ferro M, Tian Z, Saad F, Shariat S, Graefen M, Briganti A, Chun F, Terrone C, Antonelli A, De Cobelli O, Musi G, Karakiewicz P. Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00506-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
Marra G, Rajwa P, Montefusco G, Van Den Bergh R, Zattoni F, Dal Moro F, Magli A, Affentranger A, Grogg J, Hermanns T, Malkiewicz B, Kowalczyk K, Shariat S, Bianchi A, Antonelli A, Gallina S, Berchiche W, Cathelineau X, Afferi L, Fankhauser C, Mattei A, Scuderi S, Briganti A, Gontero P, Gandaglia G. Impact of pre-operative PSMA PET/CT for men with cN0M0 conventional imaging and pN+ prostate cancer: Results from a multicenter study. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00296-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
8
|
Gandaglia G, Robesti D, Bianchi L, Schiavina R, Brunocilla E, Afferi L, Mattei A, Zattoni F, Rajwa P, Shariat S, Kesch C, Sierra J, Gontero P, Marra G, Guo H, Gomez Rivas J, Zhuang J, Amparore D, Dal Moro F, Porpiglia F, Darr C, Fendler W, Picchio M, Montorsi F, Briganti A. Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00699-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
9
|
Di Trapani E, Guzzo S, Lievore E, Terrone C, Krajewski W, Xylinas E, Peroni A, Galfano A, Kelly J, Hurle R, Albisinni S, Shariat S, Teoh J, Hendricksen K, Antonelli A, Roumiguié M, Sanchez Salas R, Mir C, Soria F, Simone G, Montorsi F, Simeone C, Musi G, De Cobelli O. Evaluating the impact of complications on survival outcomes in patients treated with radical cystectomy for bladder cancer. Results from a European multi-institutional collaboration (YAU Urothelial Cancer Group). Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00200-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
10
|
Scuderi S, Gandaglia G, Mazzone E, Huebner N, Brunocilla E, Dal Moro F, Sartorello A, Ibanez L, Jesús MS, Mattei A, Afferi L, Shariat S, Wolfgang F, Picchio M, Marra G, Zattoni F, Reitano G, Rajwa P, Gomez-Rivas J, Kesch C, Porpiglia F, Amparore D, Checcucci E, Montorsi F, Briganti A. The prognostic impact of preoperative psma-pet on early oncological outcomes in prostate cancer patients treated with radical prostatectomy: Results of a multi-center analysis. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00297-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
11
|
von Deimling M, Rajwa P, Tilki D, Heidenreich A, Pallauf M, Bianchi A, Yanagisawa T, Kawada T, Karakiewicz PI, Gontero P, Pradere B, Ploussard G, Rink M, Shariat SF. The current role of precision surgery in oligometastatic prostate cancer. ESMO Open 2022; 7:100597. [PMID: 36208497 PMCID: PMC9551071 DOI: 10.1016/j.esmoop.2022.100597] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 08/31/2022] [Accepted: 09/07/2022] [Indexed: 12/30/2022] Open
Abstract
Oligometastatic prostate cancer (omPCa) is a novel intermediate disease state characterized by a limited volume of metastatic cells and specific locations. Accurate staging is paramount to unmask oligometastatic disease, as provided by prostate-specific membrane antigen-positron emission tomography. Driven by the results of prospective trials employing conventional and/or modern staging modalities, the treatment landscape of omPCa has rapidly evolved over the last years. Several treatment-related questions comprising the concept of precision strikes are under development. For example, beyond systemic therapy, cohort studies have found that cytoreductive radical prostatectomy (CRP) can confer a survival benefit in select patients with omPCa. More importantly, CRP has been consistently shown to improve long-term local symptoms when the tumor progresses across disease states due to resistance to systemic therapies. Metastasis-directed treatments have also emerged as a promising treatment option due to the visibility of oligometastatic disease and new technologies as well as treatment strategies to target the novel PCa colonies. Whether metastases are present at primary cancer diagnosis or detected upon biochemical recurrence after treatment with curative intent, targeted yet decisive elimination of disseminated tumor cell hotspots is thought to improve survival outcomes. One such strategy is salvage lymph node dissection in oligorecurrent PCa which can alter the natural history of progressive PCa. In this review, we will highlight how refinements in modern staging modalities change the classification and treatment of (oligo-)metastatic PCa. Further, we will also discuss the current role and future directions of precision surgery in omPCa.
Collapse
Affiliation(s)
- M von Deimling
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Rajwa
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
| | - D Tilki
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - A Heidenreich
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital Cologne, Cologne, Germany
| | - M Pallauf
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - A Bianchi
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - T Yanagisawa
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
| | - T Kawada
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
| | - P Gontero
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy
| | - B Pradere
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France
| | - G Ploussard
- Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France
| | - M Rink
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S F Shariat
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, USA; Department of Urology, University of Texas Southwestern, Dallas, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
| |
Collapse
|
12
|
Guzzo S, Lievore E, Di Trapani E, Mistretta F, Luzzago S, Rouprêt M, Terrone C, Laukhtina E, Simeone C, Roumiguié M, Soria F, Kelly J, Shariat S, Albisinni S, Krajewski W, Antonelli A, Ploussard G, Teoh J, Oscar RB, Montorsi F, Hurle R, Maestro MA, Xylinas E, Salas RS, Simone G, Carme M, Galfano A, Hendricksen K, Peroni A, Musi G, De Cobelli O. Evaluating the impact of complications on survival outcomes in patients treated with radical cystectomy for bladder cancer. Results from an european multi-institutional collaboration (YAU urothelial cancer group). EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01124-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
13
|
Cannoletta D, Fossati N, Karnes R, Boorjan S, Bossi A, Di Muzio N, Cozzarini C, Chiorda BN, Gandaglia G, Bartkowiak D, Shariat S, Goldner G, Berghen C, Joniau S, De Meerleer G, Scilipoti P, Mazzone E, Stabile A, van Poppel H, Gallina A, Wiegel T, Montorsi F, Briganti A. Toxicity profile of immediate post-prostatectomy radiation therapy: results from a large multi-institutional series. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01090-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
14
|
Pellegrino F, Stabile A, Mazzone E, Sorce G, Nocera L, Barletta F, Scuderi S, Toneatto L, Quarta L, Larcher A, Capitanio U, Gandaglia G, Salonia A, Rosiello G, Cirulli G, Picozzi M, Fossati N, De Cobelli F, Esposito A, Brembilla G, Shariat S, Montorsi F, Briganti A. Does previous prostatic surgery affect the accuracy of multiparametric MRI in detecting clinically significant prostate cancer? Results from a single center, high volume series. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)00993-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
15
|
Scilipoti P, Fossati N, Mazzone E, Karnes J, Boorjian S, Motterle G, Bossi A, Kumar T, Di Muzio N, Cozzarini C, Chiorda BN, Robesti D, Cirulli G, Gandaglia G, Suardi N, Bartkowiak D, Shariat S, Goldner G, Berghen C, Joniau S, Stabile A, Cucchiara V, van Poppel H, De Meerleer G, Karakiewicz P, Wiegel T, Montorsi F, Briganti A. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01089-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
16
|
Goujon A, Khene ZE, Thenault R, Vigneau C, Peyronnet B, Belabbas D, Guérin S, Chemouny J, Gasmi A, Verhoest G, Shariat S, Bensalah K, Mathieu R. Contrast-enhanced CT texture analysis for the prediction of delayed graft function following kidney transplantation from cadaveric donors. Prog Urol 2022; 32:868-874. [DOI: 10.1016/j.purol.2022.07.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 06/09/2022] [Accepted: 07/11/2022] [Indexed: 10/15/2022]
|
17
|
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:244-258. [PMID: 34861372 DOI: 10.1016/j.annonc.2021.11.012] [Citation(s) in RCA: 179] [Impact Index Per Article: 89.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 11/16/2021] [Accepted: 11/17/2021] [Indexed: 12/24/2022] Open
Affiliation(s)
- T Powles
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK
| | - J Bellmunt
- Beth Israel Deaconess Medical Centre-IMIM Lab, Harvard Medical School, Boston, USA
| | - E Comperat
- L'Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | - M De Santis
- Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - R Huddart
- Royal Marsden Hospital, Institute of Cancer Research, London, UK
| | - Y Loriot
- Département de Médecine Oncologique, Université Paris-Saclay and Gustave Roussy, Villejuif, France
| | - A Necchi
- Vita-Salute San Raffaele University, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy
| | | | - A Ravaud
- Hôpital Saint-André CHU, Bordeaux, France; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France
| | - S F Shariat
- Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
| | - B Szabados
- Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK; Department of Urology, University College London Hospital, London, UK
| | - M S van der Heijden
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - S Gillessen
- Oncology Institute of Southern Switzerland (IOSI), EOC, Lugano, Switzerland
| |
Collapse
|
18
|
Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Black PC. Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54]. Eur Urol Focus 2022; 8:1559. [PMID: 35181282 DOI: 10.1016/j.euf.2022.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Maria Carmen Mir
- Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Fundacion Instituto Valenciano Oncologia, Valencia, Spain.
| | - Michele Marchioni
- Departmentof Medical, Oral and Biotechnological Sciences, Urology Unit, University "G. d'Annunzio", Chieti-Pescara, Italy
| | - Homi Zargar
- Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
| | - K Zargar-Shoshtari
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - A S Fairey
- University of Alberta, Edmonton, Alberta, Canada
| | - Laura S Mertens
- Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - C P Dinney
- Department of Urology, MD Anderson Cancer Center, Houston, TX, USA
| | - L M Krabbe
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, University of Münster, Münster, Germany
| | - M S Cookson
- Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA
| | - N E Jacobsen
- University of Alberta, Edmonton, Alberta, Canada
| | - J Griffin
- Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA
| | - J S Montgomery
- Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA
| | - N Vasdev
- Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK
| | - E Y Yu
- Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - E Xylinas
- Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, USA; Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France
| | - J S McGrath
- Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK
| | - W Kassouf
- Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada
| | - M A Dall'Era
- Department of Urology, University of California at Davis, Davis Medical Center, Sacramento, CA, USA
| | - S S Sridhar
- Princess Margaret Hospital, Toronto, Ontario, Canada
| | - J Aning
- Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK
| | - S F Shariat
- Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, USA; Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; UT Southwestern, Dallas, TX, USA; Charles University, Prag, Czech Republic; University of Jordan, Amman, Jordan
| | - J L Wright
- Department of Urology, University of Washington, Seattle, WA, USA
| | - A C Thorpe
- Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK
| | - T M Morgan
- Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA
| | - J M Holzbeierlein
- Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA
| | - T J Bivalacqua
- Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - S North
- Cross Cancer Institute, Edmonton, AB, Canada; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - D A Barocas
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Y Lotan
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - P Grivas
- Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
| | - A J Stephenson
- Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, RUSH University, Chicago, IL, USA
| | - J B Shah
- Department of Urology, MD Anderson Cancer Center, Houston, TX, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA
| | - B W van Rhijn
- Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - P E Spiess
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - S Daneshmand
- USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA
| | - P C Black
- Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
| |
Collapse
|
19
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Rosiello G, Bravi C, Martini A, Cirulli G, Pellegrino A, De Angelis M, Necchi A, Raggi D, Cucchiara V, Suardi N, Shariat S, Montorsi F, Briganti A. The key role of concomitant androgen-deprivation therapy on the efficacy of imaging guided treatments in men with biochemical recurrent prostate cancer after radical prostatectomy and 68Ga-PSMA PET/CT scan. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00285-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Sari Motlagh R, Schuettfort V, Mori K, Katayama S, Rajwa P, Aydh A, Grossmann N, Laukhtina E, Pradere B, Mostafai H, Quhal F, Abufaraj M, Lee R, Karakiewicz P, Lotan Y, Comprate E, Moschini M, Gontero P, Shariat S. Prognostic impact of perioperative circulating levels of Insulin-like growth factor-I (IGF-I) and its binding proteins, IGFBP-2 and IGFBP-3, on disease outcomes after radical cystectomy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01159-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Barletta F, Scuderi S, Rosiello G, Stabile A, Gandaglia G, Mazzone E, Gallina A, Fossati N, Zaffuto E, Dehò F, Capitanio U, Mirone V, Larcher A, Salonia A, Karakiewicz P, Shariat S, Montorsi F, Briganti A. Topographic description of the site of positive MpMRI and impact on the risk of positive surgical margins at robot-assisted nerve sparing radical prostatectomy: Implications for accurate surgical approaches. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01244-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Gandaglia G, Mazzone E, Zaffuto E, Sorce G, Pellegrino F, Nocera L, Stabile A, Capitanio U, Larcher A, Dehò F, Salonia A, Karakiewicz P, Shariat S, Montorsi F, Briganti A. Impact of the time elapsed between prostate biopsy and surgery on the accuracy of the Briganti nomogram predicting lymph node invasion in men with clinically localized prostate cancer. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00739-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Gandaglia G, Rosiello G, Pellegrino F, Pellegrino A, Bandini M, Salonia A, Tutolo M, De Angelis M, Sorce G, Stabile A, Mazzone E, Cucchiara V, Zaffuto E, Mirone V, Karakiewicz P, Shariat S, Montorsi F, Briganti A. A more extended pelvic lymph node dissection decreases recurrence rates in selected prostate cancer patients undergoing radical prostatectomy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00752-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
De Angelis M, Mazzone E, Gandaglia G, Stabile A, Scuderi S, Barletta F, Robesti D, Nocera L, Leni R, Cucchiara V, Necchi A, Zaffuto E, Suardi N, Shariat S, Montorsi F, Briganti A. Delaying post-operative radiation therapy after radical prostatectomy is associated with increased functional outcomes: Results from a large single, referral center series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00912-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Mazzone E, Gandaglia G, Stabile A, Fossati N, Gallina A, Zaffuto E, Picozzi M, Barletta F, Scuderi S, Leni R, Nocera L, Sorce G, Pellegrino F, Rosiello G, Capitanio U, Larcher A, Lucianò R, Montironi R, Cimadamore A, Karakiewicz P, Shariat S, Montorsi F, Briganti A. Not all adverse pathology features are equal: Identifying optimal candidates for adjuvant radiotherapy among patients with adverse pathology at radical prostatectomy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00908-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Scuderi S, Cirulli G, Barletta F, De Angelis M, Toneatto L, Mazzone E, Stabile A, Gallina A, Fossati N, Zaffuto E, Dehò F, Capitanio U, Larcher A, Salonia A, Gandaglia G, Shariat S, Karakiewicz P, Montorsi F, Briganti A. When can we de-intensify treatments in ISUP Grade Group 5 prostate cancer? Long-term results of a single center, high volume series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00907-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Nocera L, Leni R, Stabile A, Gandaglia G, Cucchiara V, Rosiello G, Sorce G, Pellegrino F, Scuderi S, Barletta F, Gallina A, Fossati N, Zaffuto E, Moschini M, Suardi N, Shariat S, Montorsi F, Briganti A. Drop-out rates from active surveillance for disease progression remain consistent and not negligible over time. A plea for long-term assessment based on a large, prospectively collected active surveillance cohort. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00371-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Pellegrino F, Stabile A, Mazzone E, Sorce G, Pellegrino A, De Angelis M, Nocera L, Scuderi S, Barletta F, Cirulli G, Picozzi M, Toneatto L, Quarta L, Tutolo M, Rosiello G, Larcher A, Capitanio U, De Cobelli F, Esposito A, Brembilla G, Shariat S, Fossati N, Salonia A, Montorsi F, Briganti A. Does previous prostatic surgery affect the accuracy of multiparametric MRI in detecting clinically significant prostate cancer? Results from a single center, high volume series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00819-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Stabile A, Mazzone E, Rosiello G, Sorce G, Barletta F, Nocera L, Cucchiara V, Zaffuto E, Dehò F, Cannoletta D, Pellegrino A, De Angelis M, Scuderi S, Suardi N, Fossati N, Esposito A, De Cobelli F, Brembilla G, Shariat S, Gandaglia G, Montorsi F, Briganti A. Has the introduction of mpMRI in the diagnostic pathway of prostate cancer led to improved oncological outcomes after radical prostatectomy? Result from a large single-institutional series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00816-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Sari Motlagh R, Yanagisawa T, Kawada T, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Huebner N, Baltzer P, Karakiewicz P, Heidenreich A, Shariat S. Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: A diagnostic meta-analysis. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00566-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Fossati N, Karnes J, Heidenreich A, Kretschmer A, Buchner A, Stief C, Joniau S, Van Poppel H, Osmonov D, Jueneman K, Shariat S, Hiester A, Albers P, Tilki D, Graefen M, Gill I, Pfister D, Mazzone E, Gandaglia G, Stabile A, Gallina A, Mottrie A, Montorsi F, Briganti A. How to optimize patient selection before salvage lymph node dissection for nodal recurrent prostate cancer: A novel risk stratification tool. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00591-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Gontero P, Dominguez-Escrig J, Van Rhijn B, Mostafid A, Roupret M, Cohen D, Comperat E, Liedberg F, Palou Redorta J, Burger M, Shariat S, Seisen T, Soukup V, Masson-Lecomte A, Capoun O, Babjuk M, Sylvester R. Assessing the impact of BCG on progression of NMIBC in the new EAU high risk and very high-risk groups. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00321-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Fossati N, Karnes J, Boorjan S, Bossi A, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Mazzone E, Stabile A, Bartkowiak D, Shariat S, Goldner G, Joniau S, Berghen C, De Meerleer G, Van Poppel H, Gallina A, Montorsi F, Wiegel T, Briganti A. PSA doubling time as predictor of relapse after early salvage radiation therapy: When should imaging be used to select patients who might not benefit from early local treatments? Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00281-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Leni R, Scuderi S, Gandaglia G, Lucianò R, Tenace N, Paparesta F, Pepi L, Nocera L, Robesti D, Quarta L, Toneatto L, Stabile A, Mazzone E, Barletta F, Cimadamore A, Montironi R, Karakiewicz P, Shariat S, Dehò F, Montorsi F, Briganti A. Does centralized revision of prostate biopsy impact on active surveillance outcomes? Results from a single, high-volume institution series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00364-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Neveu P, Ouzaid I, Roumiguié M, Moschini M, Mathieu R, Verhoest G, Shariat S, Hermieu J, Xylinas E. Impact de la taille tumorale sur le pronostic des tumeurs de la voie excrétrice urinaire supérieure de bas risque. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Zhao H, Chan VWS, Castellani D, Chan EOT, Ong WLK, Peng Q, Moschini M, Krajewski W, Pradere B, Ng CF, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan WS, Kelly J, Shariat SF, Witjes JA, Teoh JYC. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Introduction
Traditional intravesical chemotherapy instillations under room temperature post trans-urethral resection (TUR) of non-muscle invasive bladder cancer (NMIBC) have lower efficacies than maintenance BCG installations. Intravesical chemo-hyperthermia (CHT) at higher temperatures is developed to improve the efficacy of chemotherapy instillation. This systematic review aims to compare the use of CHT and BCG instillation post-TUR.
Method
The protocol of this review is registered on PROSPERO(CRD42020223277). A comprehensive literature search was performed on Medline, EMBASE, and Cochrane CENTRAL to identify studies comparing CHT and BCG post-TUR for intermediate- or high-risk NMIBC. Primary outcomes include recurrence-free survival (RFS) and progression-free survival (PFS). Secondary outcomes include adverse events (AE).
Results
From 2,375 identified records, four randomised control trials incorporating 327 patients were included for meta-analysis. The use of CHT was found to be non-inferior to BCG in RFS, PFS and AEs (Grades 1-3) (p > 0.05). Sensitivity analysis, excluding patients with BCG failures, show 24-36 months recurrence rate to be significantly lower in CHT group (RR 0.64, 95% CI 0.42-0.98, p = 0.04) compared to the BCG group. In patients without carcinoma in situ (CIS), RFS is also significantly better in CHT patients (HR 0.52, 95% CI 0.32- 0.85, p < 0.01). Safety profile remains non-inferior to the BCG group in sensitivity analyses. Quality of evidence across all outcomes ranged from moderate to low.
Conclusions
In well-selected patients, intravesical CHT has superior oncological outcomes and non-inferior safety profile when compared to BCG maintenance therapy for patients with intermediate- and high-risk NMIBC. CHT is a possible alternative treatment during BCG shortage.
Collapse
Affiliation(s)
- H Zhao
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - V W S Chan
- University of Leeds, Leeds, United Kingdom
| | | | - E O T Chan
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - W L K Ong
- Penang General Hospital, Penang, Malaysia
| | - Q Peng
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - M Moschini
- Luzerner Kantonsspital, Lucerne, Switzerland
| | | | - B Pradere
- University Hospital of Tours, Tours, France
| | - C F Ng
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - D Enikeev
- Sechenov University, Moscow, Russian Federation
| | - N Vasdev
- University of Hertfordshire, Hatfield, United Kingdom
| | - G Ekin
- Urla State Hospital, İzmir, Turkey
| | - A Sousa
- Comarcal Hospital, Monforte, Spain
| | - J Leon
- Comarcal Hospital, Monforte, Spain
| | | | - W S Tan
- University College London, London, United Kingdom
- Royal Free Hospital, London, United Kingdom
| | - J Kelly
- University College London, London, United Kingdom
- Royal Free Hospital, London, United Kingdom
| | - S F Shariat
- Medical University of Vienna, Vienna, Austria
- Weill Cornell Medical College, New York, USA
- University of Texas Southwestern, Dallas, USA
- Charles University, Prague, Czech Republic
- The University of Jordan, Amman, Jordan
| | - J A Witjes
- Radboud University Medical Centre, Nijimegen, Netherlands
| | - J Y C Teoh
- The Chinese University of Hong Kong, Hong Kong, Hong Kong
| |
Collapse
|
37
|
Soria F, Barale M, D’Andrea D, Gust K, Pizzuto G, Mazzoli S, Debellis M, Rosazza M, Livoti S, Lillaz B, Shariat S, Gontero P. Skeletal muscle loss predicts oncological outcomes in T1HG patients treated with adjuvant intravesical BCG: implications for decision-making? EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00705-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
38
|
Scuderi S, Fossati N, Gandaglia G, Motterle G, Karnes R, Pfister D, Heidenreich A, Kretschmer A, Buchner A, Stief C, Devos G, Joniau S, Van Poppel H, Osmonov D, Jueneman K, Grubmuller B, Shariat S, Hiester A, Albers P, Tilki D, Graefen M, Gill I, Mottrie A, Bravi C, Montorsi F, Briganti A. Definition and impact on oncologic outcomes of persistently elevated PSA after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: clinical implications for multi-modal therapy. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00895-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
39
|
Scuderi S, Mazzone E, Heidenreich A, Gandaglia G, Pfister D, Shariat S, Bernhard G, Fossati N, Fallara G, Pellegrino A, Karnes R, Cucchiara V, Bravi C, Scuderi S, Robesti D, Leni R, Cannoletta D, Gallina A, Moschini M, Suardi N, Stabile A, Necchi A, Montorsi F, Briganti A. Which patients with oligometastatic prostate cancer should be considered for cytoreductive radical prostatectomy as part of a multimodal treatment? Results from a large, multi-institutional collaboration. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00898-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
Mazzone E, Fossati N, Karnes R, Boorjan S, Motterle G, Bossi A, Kumar T, Di Muzio N, Cozzarini C, Chiorda BN, Gandaglia G, Stabile A, Scuderi S, Bartkowiak D, Shariat S, Goldner G, Joniau S, Van Poppel H, Berghen C, De Meerleer G, Montorsi F, Wiegel T, Briganti A. There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy. a retrospective, multi-centre analyses on oncological and toxicity outcomes. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00890-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
41
|
Resch I, Bruchbacher A, Franke J, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. ESMO Open 2021; 6:100122. [PMID: 34217917 PMCID: PMC8261552 DOI: 10.1016/j.esmoop.2021.100122] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 03/14/2021] [Accepted: 04/01/2021] [Indexed: 10/26/2022] Open
Abstract
BACKGROUND Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused on ICI treatment in the first or second line. The aim of this analysis is to evaluate the benefit of ICI across different treatment lines. PATIENTS AND METHODS This is a single-center retrospective study that included mRCC patients who received ICIs in various treatment lines. Objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated. RESULTS Ninety-four patients were eligible for full evaluation. Patients were classified as International mRCC Database Consortium (IMDC) risk group categorization as good, intermediate and poor risk in 26.8%, 61.6% and 14.8% of cases, respectively. They were treated with ICI monotherapy, dual ICI therapy and ICI + tyrosine kinase inhibitor in 59%, 20% and 21% of cases, respectively. ORR, median PFS and OS for the entire cohort was 39.4%, 9.67 months [95% confidence interval (CI) 6.9-12.4 months] and 23.6 months (95% CI 13.3-33.9 months), respectively. The ORR by treatment line was 33% in first, 40.4% in the second, 35% in the third and 43.5% in the fourth line and beyond. Median PFS by treatment line was 8.6, 10.3, 7.9 and 7.23 months, respectively. The median OS was not reached in first-line treatment and was 26.2, 18.1 and 20.7 months in the second, third and fourth line and beyond, respectively. CONCLUSIONS ICIs or ICI combinations are active in all treatment lines and should also be offered in heavily pretreated patients. Patient selection based on tumor and patient factors allows for maximal benefit from ICI-based therapies.
Collapse
Affiliation(s)
- I Resch
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
| | - A Bruchbacher
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - J Franke
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - H Fajkovic
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - M Remzi
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - S F Shariat
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, USA; Department of Urology, University of Texas Southwestern, Dallas, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
| | - M Schmidinger
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
42
|
Pisano F, Gontero P, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. Actas Urol Esp 2021; 45:473-478. [PMID: 34147426 DOI: 10.1016/j.acuroe.2020.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 08/22/2020] [Indexed: 11/28/2022]
Abstract
INTRODUCTION AND OBJECTIVES The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors that may influence the presence of residual disease at re-TUR. MATERIAL AND METHODS In our retrospective cohort of 2451 primary T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. 74% had multifocal tumors, 20% of tumors were more than 3 cm in diameter and 26% had concomitant CIS. In this subgroup of patients who underwent re-TUR, there was no residual disease in 267 patients (29%) and residual disease in 667 patients (71%): Ta in 378 (40%) and T1 in 289 (31%) patients. Age, gender, tumor status (primary/recurrent), previous intravesical therapy, tumor size, tumor multi-focality, presence of concomitant CIS, and muscle in the specimen were analyzed in order to evaluate risk factors of residual disease at re-TUR, both in univariate analyses and multivariate logistic regressions. RESULTS The following were not risk factors for residual disease: age, gender, tumor status and previous intravesical chemotherapy. The following were univariate risk factors for presence of residual disease: no muscle in TUR, multiple tumors, tumors > 3 cm, and presence of concomitant CIS. Due to the correlation between tumor multi-focality and tumor size, the multivariate model retained either the number of tumors or the tumor diameter (but not both), p < 0.001. The presence of muscle in the specimen was no longer significant, while the presence of CIS only remained significant in the model with tumor size, p < 0.001. CONCLUSIONS The most significant factors for a higher risk of residual disease at re-TUR in T1G3 patients are multifocal tumors and tumors more than 3 cm. Patients with concomitant CIS and those without muscle in the specimen also have a higher risk of residual disease.
Collapse
Affiliation(s)
- F Pisano
- Città della Salute e della Scienza di Torino, University of Studies of Turin; Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain.
| | - P Gontero
- Città della Salute e della Scienza di Torino, University of Studies of Turin
| | - R Sylvester
- Formerly Department of Biostatistics, EORTC Headquarters
| | - S Joniau
- Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - V Serretta
- Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy
| | - S Larré
- Department of Surgical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK
| | - S Di Stasi
- Policlinico Tor Vergata-University of Rome, Rome, Italy
| | - B van Rhijn
- Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - A Witjes
- Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - A Grotenhuis
- Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - R Colombo
- Dipartimento di Urologia, Università Vita-Salute, Ospedale S. Raffaele, Milan, Italy
| | - A Briganti
- Dipartimento di Urologia, Università Vita-Salute, Ospedale S. Raffaele, Milan, Italy
| | - M Babjuk
- Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic
| | - V Soukup
- Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic
| | - P U Malmstrom
- Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden
| | - J Irani
- Department of Urology, Hospital Bicetre, France
| | - N Malats
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO)
| | - J Baniel
- Department of Urology, Rabin Medical Centre, Tel Aviv, Israel
| | - R Mano
- Department of Urology, Rabin Medical Centre, Tel Aviv, Israel
| | - T Cai
- Department of Urology, Santa Chiara Hospital, Trento, Italy
| | - E Cha
- Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - P Ardelt
- University Hospital Basel, Urological University Clinic Basel-Liestal, Basel, Switzerland
| | - J Varkarakis
- Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece
| | - R Bartoletti
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - G Dalbagni
- Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - S F Shariat
- Department of Urology, Medical University of Vienna, Vienna, 1190, Austria; Department of Urology, Cochin Hospital, Paris, France
| | - E Xylinas
- Department of Urology, Mayo Clinic, Rochester, MN, USA
| | - R J Karnes
- Department of Urology, Mayo Clinic, Rochester, MN, USA
| | - J Palou
- Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain
| |
Collapse
|
43
|
Moll F, Halling T, Hansson N, Shariat S, Krischel M. Early Vienna sources on the history of urology, sexual medicine and sexology. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01398-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Bravi C, Fossati N, Gandaglia G, Motterle G, Karnes R, Pfister D, Heidenreich A, Buchner A, Stief C, Devos G, Joniau S, Van Poppel H, Osmonov D, Jueneman K, Grubmuller B, Shariat S, Nini A, Hiester A, Albers P, Tilki D, Graefen M, Gill I, Mottrie A, Montorsi F, Briganti A. Assessing the association between the template of pelvic salvage lymph node dissection for node-only recurrent prostate cancer and oncological outcomes. Results of a multi-institutional series. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01561-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Mazzone E, Fossati N, Stabile A, Martini A, Karnes R, Boorjan S, Bossi A, Di Muzio N, Cozzarini C, Gandaglia G, Bartkowiak D, Böhmer D, Shariat S, Goldner G, Devos G, Joniau S, Berghen C, De Meerleer G, Van Poppel H, Necchi A, Montorsi F, Wiegel T, Briganti A. Very long-term outcomes, time patterns of recurrence and other-cause mortality in patients treated with salvage radiation therapy for recurrent prostate cancer after radical prostatectomy: Implications for risk tailored follow-up strategies. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01559-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
46
|
Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, Sareshgi RAM, Mohamad D, Hamboeck M, Rausch I, Mitterhauser M, Wadsak W, Haug AR, Kenner L, Mazal P, Susani M, Hartenbach S, Baltzer P, Helbich TH, Kramer G, Shariat SF, Beyer T, Hartenbach M, Hacker M. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [ 68Ga]Ga-PSMA-11 PET/MRI. Eur J Nucl Med Mol Imaging 2021; 48:1795-1805. [PMID: 33341915 PMCID: PMC8113201 DOI: 10.1007/s00259-020-05140-y] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 11/29/2020] [Indexed: 12/13/2022]
Abstract
PURPOSE Risk classification of primary prostate cancer in clinical routine is mainly based on prostate-specific antigen (PSA) levels, Gleason scores from biopsy samples, and tumor-nodes-metastasis (TNM) staging. This study aimed to investigate the diagnostic performance of positron emission tomography/magnetic resonance imaging (PET/MRI) in vivo models for predicting low-vs-high lesion risk (LH) as well as biochemical recurrence (BCR) and overall patient risk (OPR) with machine learning. METHODS Fifty-two patients who underwent multi-parametric dual-tracer [18F]FMC and [68Ga]Ga-PSMA-11 PET/MRI as well as radical prostatectomy between 2014 and 2015 were included as part of a single-center pilot to a randomized prospective trial (NCT02659527). Radiomics in combination with ensemble machine learning was applied including the [68Ga]Ga-PSMA-11 PET, the apparent diffusion coefficient, and the transverse relaxation time-weighted MRI scans of each patient to establish a low-vs-high risk lesion prediction model (MLH). Furthermore, MBCR and MOPR predictive model schemes were built by combining MLH, PSA, and clinical stage values of patients. Performance evaluation of the established models was performed with 1000-fold Monte Carlo (MC) cross-validation. Results were additionally compared to conventional [68Ga]Ga-PSMA-11 standardized uptake value (SUV) analyses. RESULTS The area under the receiver operator characteristic curve (AUC) of the MLH model (0.86) was higher than the AUC of the [68Ga]Ga-PSMA-11 SUVmax analysis (0.80). MC cross-validation revealed 89% and 91% accuracies with 0.90 and 0.94 AUCs for the MBCR and MOPR models respectively, while standard routine analysis based on PSA, biopsy Gleason score, and TNM staging resulted in 69% and 70% accuracies to predict BCR and OPR respectively. CONCLUSION Our results demonstrate the potential to enhance risk classification in primary prostate cancer patients built on PET/MRI radiomics and machine learning without biopsy sampling.
Collapse
Affiliation(s)
- L Papp
- QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
| | - C P Spielvogel
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria
| | - B Grubmüller
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - M Grahovac
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - D Krajnc
- QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
| | - B Ecsedi
- QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
| | - R A M Sareshgi
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - D Mohamad
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - M Hamboeck
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - I Rausch
- QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
| | - M Mitterhauser
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
| | - W Wadsak
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - A R Haug
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria
| | - L Kenner
- Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | - P Mazal
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | - M Susani
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | | | - P Baltzer
- Department of Biomedical Imaging and Image-guided Therapy, Division of Common General and Pediatric Radiology, Medical University of Vienna, Vienna, Austria
| | - T H Helbich
- Department of Biomedical Imaging and Image-guided Therapy, Division of Common General and Pediatric Radiology, Medical University of Vienna, Vienna, Austria
| | - G Kramer
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - S F Shariat
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - T Beyer
- QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
| | - M Hartenbach
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - M Hacker
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
47
|
Fossati N, Mazzone E, Karnes R, Boorjian S, Motterle G, Bossi A, Kumar T, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Stabile A, Cucchiara V, Robesti D, Bartkowiak D, Shariat S, Goldner G, Joniau S, Van Poppel H, Berghen C, De Meerleer G, Montorsi F, Wiegel T, Briganti A. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 Prostate Cancer? Results form a large Multi-Institutional series. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01591-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Scuderi S, Mazzone E, Heidenreich A, Gandaglia G, Pfister D, Shariat S, Grubmuller B, Fossati N, Fallara G, Pellegrino A, Karnes R, Cucchiara V, Bravi C, Scuderi S, Robesti D, Leni R, Cannoletta D, Gallina A, Moschini M, Suardi N, Stabile A, Necchi A, Montorsi F, Briganti A. Which patients with Oligometastatic Prostate Cancer should be considered for Cytoreductive Radical Prostatectomy as part of a multimodal treatment? Results from a large, multi-institutional collaboration. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01219-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
49
|
Fossati N, Mazzone E, Karnes R, Boorjian S, Motterle G, Bossi A, Kumar T, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Stabile A, Cucchiara V, Scuderi S, Robesti D, Bartkowiak D, Shariat S, Goldner G, Joniau S, Van Poppel H, Berghen C, De Meerleer G, Montorsi F, Wiegel T, Briganti A. Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treated with post-prostatectomy radiation therapy: Results from a large, multi-institutional study. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01549-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
50
|
Mazzone E, Fossati N, Karnes R, Boorjan S, Motterle G, Bossi A, Kumar T, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Stabile A, Scuderi S, Bartkowiak D, Shariat S, Goldner G, Joniau S, Van Poppel H, Berghen C, De Meerleer G, Montorsi F, Wiegel T, Briganti A. There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent Prostate Cancer after Radical Prostatectomy. A retrospective, multi-centre analyses on oncological and toxicity outcomes. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01552-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|